MRD in AML: who, what, when, where, and how?

Blood. 2024 Jan 25;143(4):296-298. doi: 10.1182/blood.2023022226.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Bridged Bicyclo Compounds, Heterocyclic*
  • Humans
  • Leukemia, Myeloid, Acute* / diagnosis
  • Leukemia, Myeloid, Acute* / therapy
  • Nuclear Proteins
  • Prognosis
  • Sulfonamides*

Substances

  • venetoclax
  • Bridged Bicyclo Compounds, Heterocyclic
  • Nuclear Proteins
  • Sulfonamides